Evaluation of the pol /S Gene Overlapping Mutations in Chronic Hepatitis B Patients in Northern Cyprus
, , , , et | 03 sept. 2019
À propos de cet article
Article Category: original-paper
Publié en ligne: 03 sept. 2019
Pages: 317 - 322
Reçu: 22 févr. 2019
Accepté: 13 mai 2019
DOI: https://doi.org/10.33073/pjm-2019-034
Mots clés
© 2019 Anton Pyskun et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Typical HBsAg escape and combined mutations of the study patients (n = 68).
| Typical HBsAg escape mutation | Mutation patterns | n (%) | Combined mutations | Mutation patterns | n (%) |
|---|---|---|---|---|---|
| Immune escape | sY100C, sI110L, sP120L/R, sTl23N, sT127L, sP127T, sA128V, sT131N, sS132P, sY134F/H, sT140I/S, sS143T, sD144E, sS144T, sP210S | 16 (24) | Immune response -vaccine | sI110L + sS193L | 1 (1.5) |
| Vaccine escape | sT126I, sD144A/E, sG145A/R, S193L, sP210T | 7 (10) | Vaccine-HBIg | sP120L + sT123N + sT126I + sA128V + sY134H + sD144E + sG145A | 1 (1.5) |
| HBIg | sT118A, sP120T, sD144A/E, sG145A/E/R | 4 (6) | Immune response -HBIg | sT118A + sP127T | 1 (1.5) |
| Diagnostic escape | sT118A, sT131I, sP120T, sC121Y, sD144A, sG145R | 3 (4) | Immune response-vaccine-HBIg | sI110L + sP120T + sD144A + sG145R sP120R + sC121Y, sT131I + sS132P | 1 (1.5) |
| Total | 30 (44) | 6 (9) |
Demographic and clinical characteristics of the study group.
| Variable | Study Group |
|---|---|
| Patient, n | 100 |
| Gender, F/M, n (%) | 13 (13%)/87 (87%) |
| Age, median year (range) | 35 (18-65) |
| Nationality, region/country, n (%) | |
| | |
| Turkey | 43 (63) |
| Northern Cyprus | 14 (21) |
| Pakistan | 3 (4) |
| China | 3 (4) |
| Turkmenistan | 3 (4) |
| Syria | 1 (2) |
| Georgia | 1 (2) |
| | |
| Nigeria | 28 (97) |
| Benguela | 1 (3) |
| | |
| Mexican | 1 (100) |
| | |
| Azerbaijan | 1 (50) |
| Bulgaria | 1 (50) |
| Anti HBc IgG positivity, n (%) | 96 (96) |
| HBeAg positivity, n (%) | 5 (5) |
| ALT (average ± SD) (U/L) | 23 ± 19 |
| AST (average ± SD) (U/L) | 28 ± 19 |
| HBV DNA median IU/ml (range) | 1.0 + E7 |
| Genotype/subgenotype of HBV, n (%) | |
| D1 | 48 (70.6) |
| D2 | 4 (5.9) |
| D3 | 1 (1.5) |
| A1 | 5 (7.3) |
| A2 | 2 (2.9) |
| Treatment status, n (%) | |
| Naive | 100 (100%) |
| Under treatment | - |
Mutation characteristics of the HBV pol/S gene mutation patterns to the nucleos(t)ide analogues in treatment naïve HBV carriers.
| HBV virion | Mutation characteristic | Mutation pattern | Nucleos(t)ide analogues | n (%) |
|---|---|---|---|---|
| Primary resistance mutation | ND | ND | - | |
| Compensatory mutation | rtL91I | LdT related | 25 (36.8) |